Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -93.97% is 982% below its 4-year average of 10.65%, near the high end of its 4-year range (-744.11%–39.41%).
As of the fiscal period ended Tuesday, June 30, 2026. 52.78% above its 12-month average of -199.02%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -93.97%.
RETURN ON EQUITY (ROE)
-93.97%
RETURN ON EQUITY (ROE) AVG TTM
-199.02%
RETURN ON EQUITY (ROE) AVG 3Y
-149.99%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+52.78%
CURRENT VS 3Y AVG
+37.35%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-123.69%
vs the sector median at left
Aspire Biopharma Holdings, Inc.
Market Cap
$1.01M
Return on Equity (ROE)
-93.97%
TTM Avg
-199.02%
3Y Avg
-149.99%
5Y Avg
N/A
Market Cap
$946332.00
Return on Equity (ROE)
-21.18%
TTM Avg
-23.90%
3Y Avg
-48.17%
5Y Avg
-962.79%
Market Cap
$1.08M
Return on Equity (ROE)
-57.87%
TTM Avg
-222.45%
3Y Avg
-164.72%
5Y Avg
-135.78%
Market Cap
$1.12M
Return on Equity (ROE)
-200.63%
TTM Avg
-312.18%
3Y Avg
-122.70%
5Y Avg
-56.14%
Market Cap
$901902.00
Return on Equity (ROE)
N/A
TTM Avg
-255.88%
3Y Avg
-273.58%
5Y Avg
-200.54%
Market Cap
$1.13M
Return on Equity (ROE)
-11.85%
TTM Avg
-6.20%
3Y Avg
47.36%
5Y Avg
47.36%
Market Cap
$868077.00
Return on Equity (ROE)
-73.66%
TTM Avg
-87.93%
3Y Avg
-127.18%
5Y Avg
-86.65%
Market Cap
$1.17M
Return on Equity (ROE)
N/A
TTM Avg
558.67%
3Y Avg
54.46%
5Y Avg
-8.27%
Market Cap
$838843.00
Return on Equity (ROE)
-77.23%
TTM Avg
-124.66%
3Y Avg
-168.43%
5Y Avg
-110.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | $1.01M | -93.97% | -199.02% | -149.99% | N/A |
| Sunshine Biopharma, Inc. (SBFM)vs › | $946332.00 | -21.18% | -23.90% | -48.17% | -962.79% |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | -57.87% | -222.45% | -164.72% | -135.78% |
| Propanc Biopharma, Inc. (PPCB)vs › | $1.12M | -200.63% | -312.18% | -122.70% | -56.14% |
| GlucoTrack, Inc. (GCTK)vs › | $901902.00 | N/A | -255.88% | -273.58% | -200.54% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.13M | -11.85% | -6.20% | 47.36% | 47.36% |
| Bone Biologics Corporation (BBLG)vs › | $868077.00 | -73.66% | -87.93% | -127.18% | -86.65% |
| IM Cannabis Corp. (IMCC)vs › | $1.17M | N/A | 558.67% | 54.46% | -8.27% |
| Bluejay Diagnostics, Inc. (BJDX)vs › | $838843.00 | -77.23% | -124.66% | -168.43% | -110.88% |
| Ridgetech, Inc. (RDGT)vs › | $835994.00 | N/A | 15.66% | -28.27% | -26.31% |
ROE
-94.0%
ROA
-81.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -93.97% |
| 2026-03-31 | -304.06% |
| 2024-06-30 | -744.11% |
| 2024-03-31 | -4.98% |
| 2023-12-31 | 22.80% |
| 2023-09-30 | 34.96% |
| 2023-06-30 | 39.41% |
| 2023-03-31 | 2.16% |
| 2022-12-31 | 1.16% |
| 2022-09-30 | 0.39% |
| 2022-06-30 | 0.01% |
| 2022-03-31 | -0.04% |
